Table 1 Characteristics of the study sample according to the intake of systemic antiherpetic drugs. “Echantillon Généraliste des Bénéficiaires.” 2009–2017
From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?
Study sample (N=68291)N (%) | No systemic antiherpetics (N=61649)N (%) | Systemic antiherpetics (N=6642) N (%) | |
|---|---|---|---|
Age at inclusion, mean ± standard deviation | 76 ± 8 | 76 ± 8 | 74 ± 6 |
Sex - men | 28286 (41.42) | 25975 (42.13) | 2311 (34.79) |
Complementary health insurance for low-income people at inclusion | 883 (1.29) | 799 (1.30) | 84 (1.26) |
Comorbidities at inclusion | |||
Hypertension | 40471 (59.26) | 36400 (59.04) | 4071 (61.29) |
Diabetes | 10584 (15.50) | 9668 (15.68) | 916 (13.79) |
Heart disease | 19753 (28.92) | 17866 (28.98) | 1887 (28.41) |
Stroke | 1294 (1.89) | 1194 (1.94) | 100 (1.51) |
Hypercholesterolemia | 25590 (37.47) | 22737 (36.88) | 2853 (42.95) |
Intake of nonsteroidal anti-inflammatory drugs the year before inclusion | |||
0 | 43184 (63.24) | 39695 (64.39) | 3489 (52.53) |
1 à 10 | 20246 (29.65) | 17735 (28.77) | 2511 (37.80) |
≥10 | 4861 (7.12) | 4219 (6.84) | 642 (9.67) |
Intake of systemic glucocorticoids the year before inclusion | |||
0 | 55301 (80.98) | 50385 (81.73) | 4916 (74.01) |
1 à 10 | 12081 (17.69) | 10465 (16.98) | 1615 (24.31) |
≥10 | 910 (1.33) | 799 (1.30) | 111 (1.67) |
Intake of inhaled glucocorticoids the year before inclusion | |||
0 | 61175 (89.58) | 55429 (89.91) | 5746 (86.51) |
1 à 10 | 5730 (8.39) | 4975 (8.07) | 755 (11.37) |
≥10 | 1386 (2.03) | 1245 (2.02) | 141 (2.12) |
Number of outpatient medical consultations the year before inclusion, median [IQR] | 2 [0–6] | 2 [0–6] | 4 [1–8] |
Number of different treatments the year before inclusion, median [IQR] | 12 [6–18] | 11 [5–18] | 15 [9–21] |